Mangalam Drugs & Organics Intrinsic Value
Mangalam Drugs & Organics (MANGALAM) median intrinsic value is ₹70.33 from 3 valuation models (range ₹56–₹70), vs current price ₹28.13 — +150.0% upside (Trading Below Calculated Value), margin of safety 60.0%. Analyse Mangalam Drugs & Organics ownership pattern to track promoter, FII and institutional holdings.
MANGALAM Valuation Methods Summary — DCF, Graham Number & P/E
Mangalam Drugs & Organics intrinsic value across 3 models vs current price ₹28.13 — upside/downside and value range per method. Read MANGALAM dividend growth for the complete payout history and dividend yield track record.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| Book Value Method | asset | ₹70.33 | ₹63.30 - ₹77.36 | +150.0% | Book Value/Share: ₹64.38, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹56.26 | ₹50.63 - ₹61.89 | +100.0% | Revenue/Share: ₹167.50, P/S: 2.0x |
| Simple DCF (5Y) | dcf | ₹70.33 | ₹56.26 - ₹84.40 | +150.0% | CF Growth: 15.0%, Discount: 15% |
MANGALAM Intrinsic Value vs Market Price — All Valuation Models
Mangalam Drugs & Organics fair value range ₹56–₹70 vs current market price ₹28.13 across 3 valuation models. For current market price and key ratios, visit Mangalam Drugs & Organics screener.
MANGALAM Intrinsic Value Analysis — Undervalued or Overvalued?
Mangalam Drugs & Organics median intrinsic value ₹70.33, current price ₹28.13 — Trading Below Calculated Value by 150.0%, margin of safety 60.0%.
What is the intrinsic value of MANGALAM?
Based on our comprehensive analysis using 3 different valuation methods, the estimated intrinsic value of Mangalam Drugs & Organics (MANGALAM) is ₹70.33 (median value). With the current market price of ₹28.13, this represents a +150.0% variance from our estimated fair value.
The valuation range spans from ₹56.26 to ₹70.33, indicating ₹56.26 - ₹70.33.
Is MANGALAM undervalued or overvalued?
Based on our multi-method analysis, Mangalam Drugs & Organics (MANGALAM) appears to be trading below calculated value by approximately 150.0%.
MANGALAM Financial Health — Key Ratios vs Industry Benchmarks
Mangalam Drugs & Organics financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 10.40 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Return on Equity | -50.5% | Industry Standard: 15%+ | Below 10% | Measures shareholder return efficiency |
| Operating Margin | -8.0% | Industry Standard: 20%+ | Below 10% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.85x | Industry Standard: 1.0x+ | Above 0.5x | Measures asset utilization efficiency |
MANGALAM Cash Flow Quality — Operating & Free Cash Flow
Mangalam Drugs & Organics operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹43 Cr | ₹33 Cr | Positive Free Cash Flow | 8/10 |
| March 2024 | ₹4 Cr | ₹-2 Cr | Positive Operating Cash Flow | 6/10 |